Laurent Alric

Laurent Alric

Auto-generated profile, based on publicly available information

Laurent Alric

Internal Medicine and Digestive Department, Rangueil Hospital Toulouse University, Toulouse, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2016 in Blood
Verified
Journal Article
Closed access
PDF file
LALuca Arcaini
Luca Arcaini
CBCaroline Besson
Caroline Besson
MFMarco Frigeni
Marco Frigeni
HFHélène Fontaine
Hélène Fontaine
MGMaria Goldaniga
Maria Goldaniga
OHOlivier Hermine
Olivier Hermine
Regression of hepatitis C virus (HCV)–associated lymphoma with interferon (IFN)-based antiviral treatment supports an etiological link between lymphoma and HCV infection. In addition, a favorable impact of antiviral treatment on overall survival of patients with HCV-related lymphoma has been reported. Data on IFN-free regimens combining direct-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty. We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leukemia (CLL) and chronic HCV infection treated with DAAs. The histological distribution was 37 marginal zone lymphomas (MZLs), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL not otherwise specified. Thirty-nine patients received a sofosbuvir-based regimen and 7 patients received other DAAs. The median duration of DAA therapy was 12 weeks (range, 6-24 weeks). A sustained virological response at week 12 after finishing DAAs was obtained in 45 patients (98%); the overall LDR rate was 67%, including 12 patients (26%) who achieved a complete response. The LDR rate was 73% among patients with MZL, whereas no response was observed in CLL/SLL patients. Seven patients cleared cryoglobulins out of 15 who were initially positive. After a median follow-up of 8 months, 1-year progression-free and overall survival rates were 75% (95% confidence interval [CI], 51-88] and 98% [95% CI, 86-100], respectively. DAA therapy induces a high LDR rate in HCV-associated indolent lymphomas. These data provide a strong rationale for prospective trials with DAAs in this setting. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Direct-acting antiviral agents are able to induce lymphoma response in patients with HCV-associated indolent non-Hodgkin lymphoma. The highest rate of lymphoma response (73%) was observed in patients with marginal zone lymphoma.

1 April 2004 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
LALaurent Alric
Laurent Alric
EPEmmanuelle Plaisier
Emmanuelle Plaisier
STSophie Thébault
Sophie Thébault
JPJean-Marie Péron
Jean-Marie Péron
LRLionel Rostaing
Lionel Rostaing
PCPatrice CACOUB
Patrice CACOUB

19 September 2017 in Hepatology
Verified
Journal Article
Open access
PDF file
DWDavid Wyles
David Wyles
FPFred Poordad
Fred Poordad
SWStanley Wang
Stanley Wang
LALaurent Alric
Laurent Alric
FFFranco Felizarta
Franco Felizarta
FMFederico J. Mensa
Federico J. Mensa
This study assessed the efficacy and safety of ribavirin‐free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options. SURVEYOR‐II, Part 3 was a partially randomized, open‐label, multicenter, phase 3 study. Treatment‐experienced (prior interferon or pegylated interferon ± ribavirin or sofosbuvir plus ribavirin ± pegylated interferon therapy) patients without cirrhosis were randomized 1:1 to receive 12 or 16 weeks of G/P (300 mg/120 mg) once daily. Treatment‐naive or treatment‐experienced patients with compensated cirrhosis were treated with G/P for 12 or 16 weeks, respectively. The primary efficacy endpoint was the percentage of patients with sustained virologic response at posttreatment week 12 (SVR12). Safety was evaluated throughout the study. There were 131 patients enrolled and treated. Among treatment‐experienced patients without cirrhosis, SVR12 was achieved by 91% (20/22; 95% confidence interval [CI], 72‐97) and 95% (21/22; 95% CI, 78‐99) of patients treated with G/P for 12 or 16 weeks, respectively. Among those with cirrhosis, SVR12 was achieved by 98% (39/40; 95% CI, 87‐99) of treatment‐naive patients treated for 12 weeks and 96% (45/47; 95% CI, 86‐99) of patients with prior treatment experience treated for 16 weeks. No adverse events led to discontinuation of study drug, and no serious adverse events were related to study drug. Conclusion: Patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis achieved high SVR12 rates following 12 or 16 weeks of treatment with G/P. The regimen was well tolerated. (Hepatology 2018;67:514‐523).

6 March 2023 in JHEP Reports
Verified
Journal Article
Open access
LHLina Hountondji
Lina Hountondji
CMChristophe Ferreira De Matos
Christophe Ferreira De Matos
FLFanny Lebossé
Fanny Lebossé
XQXavier Quantin
Xavier Quantin
CLCandice Lesage
Candice Lesage
LMLucy Meunier
Lucy Meunier
Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer therapy. Liver toxicity occurs in up to 25% of patients treated with ICIs. The aim of our study was to describe the different clinical patterns of ICI-induced hepatitis and to assess their outcome. We conducted a retrospective observational study of patients with checkpoint inhibitor-induced liver injury (CHILI) discussed in multidisciplinary meetings between December 2018 and March 2022 in three French centres specialised in ICI toxicity management (Montpellier, Toulouse, Lyon). The hepatitis clinical pattern was analysed by the ratio of serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (R value = (ALT/ULN)/(ALP/ULN)) for characterisation as cholestatic (R ≤2), hepatocellular (R ≥5), or mixed (2 <R <5). We included 117 patients with CHILI. The clinical pattern was hepatocellular in 38.5%, cholestatic in 36.8%, and mixed in 24.8% of patients. High-grade hepatitis severity (grade ≥3 according to the Common Terminology Criteria for Adverse Events system) was significantly associated with the hepatocellular hepatitis (p <0.05). No cases of severe acute hepatitis were reported. Liver biopsy was performed in 41.9% of patients: granulomatous lesions, endothelitis, or lymphocytic cholangitis were described. Biliary stenosis occurred in eight patients (6.8%) and was significantly more frequent in the cholestatic clinical pattern (p < 0.001). Steroids alone were mainly administered to patients with a hepatocellular clinical pattern (26.5%), and ursodeoxycholic acid was more frequently used in the cholestatic pattern (19.7%) than in the hepatocellular or mixed clinical pattern (p <0.001). Seventeen patients improved without any treatment. Among the 51 patients (43.6%) rechallenged with ICIs, 12 (23.5%) developed CHILI recurrence. This large cohort indicates the different clinical patterns of ICI-induced liver injury and highlights that the cholestatic and hepatocellular patterns are the most frequent with different outcomes. ICIs can induce hepatitis. In this retrospective series, we report 117 cases of ICI-induced hepatitis, mostly grades 3 and 4. We find a similar distribution of the different patterns of hepatitis. ICI could be resumed without systematic recurrence of hepatitis.

1 November 2002 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
LALaurent Alric
Laurent Alric
VDVincent Di–Martino
Vincent Di–Martino
JSJanik Selves
Janik Selves
PCPatrice CACOUB
Patrice CACOUB
FCFrédéric Charlotte
Frédéric Charlotte
LRLionel Rostaing
Lionel Rostaing

1 February 2006 in Kidney International
Verified
Journal Article
Closed access
Nassim KamarNassim Kamar
Nassim Kamar
LRL. Rostaing
L. Rostaing
LAL. Alric
L. Alric